Rapamycin affects early fracture healing in mice

British Journal of Pharmacology

Volumn 154, Issue 5, 2008, Pages 1055-1062

  Holstein, J H ^a,b,c   Klein, M ^a,b   Garcia, P ^a,b   Histing, T ^a,b   Culemann, U ^a   Pizanis, A ^a   Laschke, M W ^b   Scheuer, C ^b   Meier, C ^b   Schorr, H ^c   Pohlemann, T ^a   Menger, M D ^b  

^a Department of Trauma Hand and Reconstructive Surgery ^*  (Germany)

^b Institute for Clinical and Experimental Surgery   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Biomechanics; Cell proliferation; Fracture healing; Immunosuppression; Rapamycin; VEGF

Indexed keywords

CYCLINE; RAPAMYCIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE RADIOGRAPHY; BONE REMODELING; CALLUS; CARTILAGE CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMUR FRACTURE; FRACTURE HEALING; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PERIOSTEUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RIGIDITY; TORSION; WESTERN BLOTTING; X RAY ANALYSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOMECHANICS; BLOTTING, WESTERN; BONY CALLUS; CELL PROLIFERATION; CHONDROCYTES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMORAL FRACTURES; FRACTURE HEALING; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOBLASTS; OSTEOGENESIS; SIROLIMUS; TIME FACTORS;

EID: 46249094677     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.167     Document Type: Article

References (31)

1. Alvarez-Garcia O, Carbajo-Perez E, Garcia E, Gil H, Molinos I, Rodriguez J et al. (2007). Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 7: 954-961.
2. Andrew JG, Andrew SM, Freemont AJ, Marsh DR (1994). Inflammatory cells in normal human fracture healing. Acta Orthop Scand 65: 462-466.
3. Compston JE (2003). Osteoporosis after liver transplantation. Liver Transpl 9: 321-330.
4. Cross SE, Richards SK, Clark A, Benest AV, Bates DO, Mathieson PW et al. (2007). Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs. Diabetologia 50: 1423-1432.
5. Ferguson C, Alpern E, Miclau T, Helms JA (1999). Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 87: 57-66.
6. Geiger F, Bertram H, Berger I, Lorenz H, Wall O, Eckhardt C et al. (2005). Vascular endothelial growth factor gene-activated matrix (VEGF(165)-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. J Bone Miner Res 20: 2028-2035.
7. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999). VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628.
8. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135.
9. Holstein JH, Menger MD, Meier C, Culemann U, Pohlemann T (2007a). Development of a locking femur nail for mice. J Biomech 40: 215-219.
10. Holstein JH, Menger MD, Scheuer C, Meier C, Culemann U, Wirbel RJ et al. (2007b). Erythropoietin (EPO) - EPO-receptor signalling improves early endochondral ossification and mechanical strength in fracture healing. Life Sci 80: 893-900.
11. Isomoto S, Hattori K, Ohgushi H, Nakajima H, Tanaka Y, Takakura Y (2007). Rapamycin as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells. J Orthop Sci 1: 83-88.
12. Iwaki A, Jingushi S, Oda Y, Izumi T, Shida JI, Tsuneyoshi M et al. (1997). Localization and quantification of proliferating cells during rat fracture repair: detection of proliferating cell nuclear antigen by immunohistochemistry. J Bone Miner Res 12: 96-102.
13. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW (2006). Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 19: 607-620.
14. Laschke MW, Elitzsch A, Scheuer C, Holstein JH, Vollmar B, Menger MD (2006). Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 149: 137-144.
15. MacDonald A, Scarola J, Burke JT, Zimmerman JJ (2000). Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22S: B101-B121.
16. Miclau T, Helms JA (2000). Molecular aspects of fracture healing. Curr Opin Orthop 11: 367-371.
17. Müller ME, Nazarian S, Koch P, Schatzker J (1990). The Comprehensive Classification of Fractures of Long Bones. Springer-Verlag: Heidelberg New York.
18. Navasa M, Forns X, Sanchez V, Andreu H, Marcos V, Borras JM et al. (1996). Quality of life, major medical complications and hospital service utilization in patients with primary cirrhosis after liver transplantation. J Hepatol 25: 129-134.
19. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-23.
20. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ et al. (1987). Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610.
21. Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG et al. (1995). Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 10: 760-768.
22. Santavirta S, Konttinen YT, Nordstrom D, Makela A, Sorsa T, Hukkanen M et al. (1992). Immunologic studies of nonunited fractures. Acta Orthop Scand 63: 579-586.
23. Schaffer M, Schier R, Napirei M, Michalski S, Traska T, Viebahn R (2007). Sirolimus impairs wound healing. Langenbecks Arch Surg 392: 297-303.
24. Schmelzle T, Hall MN (2000). TOR, a central controller of cell growth. Cell 103: 253-262.
25. Singha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J et al. (2008). Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 103: 434-446.
26. Stempfle HU, Werner C, Siebert U, Assum T, Wehr U, Rambeck WA et al. (2002). The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 73: 547-552.
27. Voggenreiter G, Siozos P, Hunkemoller E, Heute S, Schwarz M, Obertacke U (2005). Immunosuppression with FK506 has no influence on fracture healing in the rat. Bone 37: 227-233.
28. Vossen M, Edelstein J, Majzoub RK, Maldonado C, Perez-Abadia G, Voor MJ et al. (2005). Bone quality and healing in a swine vascularized bone allotransplantation model using cyclosporine-based immunosuppression therapy. Plast Reconstr Surg 115: 529-538.
29. Wallemacq PE, Vanbinst R, Asta S, Cooper DP (2003). High-throughput liquid chromatography-tandem mass spectrometric analysis of sirolimus in whole blood. Clin Chem Lab Med 41: 921-925.
30. Warren SB, Pelker RR, Friedlaender GE (1985). Effects of short-term cyclosporin-A on biomechanical properties of intact and fractured bone in the rat. J Orthop Res 3: 96-100.
31. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT (1995). Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1: 53-71.